// App-Quantinova.ai

3086 : In situ, therapeutic vaccination against refractory solid cancers with intratumoral Poly-ICLC: A phase I study.

Researchers

Presenter

  • Chrisann Kyi

Principal Investigators

  • Rachel Lubong Sabado

  • Yvonne M. Saenger

  • Marshall R. Posner

  • Michael Donovan

  • William Loging

  • Erlinda Sacris

  • John P Mandeli

  • Tin Htwe Thin

  • Krzysztof Misiukiewicz

  • Robert G. Maki

  • Andres M. Salazar

  • Philip Adam Friedlander

  • Nina Bhardwaj

Medical Centers

  • Tisch Cancer Center, Mount Sinai School of Medicine, New York, NY

  • Icahn School of Medicine at Mount Sinai, New York, NY

  • Columbia University, New York, NY

  • Hematology and Medical Oncology, Icahn School of Medicine at Mount Sinai, New York, NY

  • Mount Sinai School of Medicine, New York, NY

  • Oncovir Inc., Washington, DC

  • The Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY

Locations

  • United States

Companies

  • Oncovir, Inc.

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Squamous cell carcinoma of the head and neck

  • Melanoma

  • Solid malignancies

Biomarkers

  • N/A

Drug/Treatment

  • Poly-ICLC

Outcome

  • N/A

Study Design

  • N/A

Phase

  • I

Study Id's

  • NCT01984892

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved